Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Operating Expenses: 2010-2025

Historic Other Operating Expenses for Ironwood Pharmaceuticals (IRWD) over the last 11 years, with Sep 2025 value amounting to $2.2 million.

  • Ironwood Pharmaceuticals' Other Operating Expenses rose 13650.00% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 152.82%. This contributed to the annual value of $2.6 million for FY2024, which is 99.77% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Other Operating Expenses stood at $2.2 million, which was up 980.00% from -$250,000 recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Other Operating Expenses high stood at $1.1 billion for Q2 2023, and its period low was -$250,000 during Q2 2025.
  • For the 3-year period, Ironwood Pharmaceuticals' Other Operating Expenses averaged around $116.5 million, with its median value being $2.1 million (2024).
  • Data for Ironwood Pharmaceuticals' Other Operating Expenses shows a peak YoY increase of 13,650.00% (in 2025) and a maximum YoY decrease of 112.09% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Ironwood Pharmaceuticals' Other Operating Expenses stood at $5.6 million in 2023, then tumbled by 98.70% to $73,000 in 2024, then surged by 13,650.00% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, -$250,000 for Q2 2025, and $18.6 million during Q1 2025.